{
    "Trade/Device Name(s)": [
        "Free Testosterone AccuBind ELISA Test System"
    ],
    "Submitter Information": "Monobind Inc.",
    "510(k) Number": "K181017",
    "Predicate Device Reference 510(k) Number(s)": [
        "K030730"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "July 20, 2018",
    "Summary Letter Received Date": "June 19, 2018",
    "Submission Date": "July 12, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Free testosterone"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microtiter plate reader"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Competitive immunoassay"
    ],
    "Methodologies": [
        "Colorimetric detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control",
        "Microplate",
        "Conjugate",
        "Substrate",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for Free Testosterone AccuBind ELISA Test System for quantitative measurement of free testosterone in human serum using competitive enzyme immunoassay",
    "Indications for Use Summary": "Quantitative measurement of free testosterone in human serum to aid in diagnosis and treatment of male sex hormone (androgen) disorders, including hypogonadism, impotence, hirsutism, virilization, tumors, polycystic ovaries, and adrenogenital syndromes",
    "fda_folder": "Clinical Chemistry"
}